Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
29
Apr
Shionogi & Co.,Ltd. JP3347200002
2026-04-28 Shionogi & Co.,Ltd. “Regarding our participation in the World Economic Forum and our signing of the Davos Compact on AMR: Contributing to the resolution of global healthcare challenges, including AMR, through global collaboration.”
28
Apr
Shionogi & Co.,Ltd. JP3347200002
2026-04-27 Shionogi & Co.,Ltd. “Notice Regarding Revision of Dividend Forecast (Increase in Dividend) for the Fiscal Year Ending March 2026.”
28
Apr
Astellas Pharma Inc. JP3942400007
2026-04-27 Astellas Pharma Inc. “Financial statements for fiscal year 2025.”
28
Apr
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-04-27 Sumitomo Pharma Co.,Ltd. “Notice Regarding the Withdrawal of Registration for the Issuance of New Shares.”
28
Apr
Shionogi & Co.,Ltd. JP3347200002
2026-04-27 Shionogi & Co.,Ltd. “Notice Regarding the Absorption Merger (Simplified Merger/Short-Form Merger) of Torii Pharmaceutical Co., Ltd., a Wholly Owned Subsidiary of Our Company.”
25
Apr
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-04-24 CHUGAI PHARMACEUTICAL CO.,LTD. “Notice Regarding the Detailed Decision on Stock Acquisition in Connection with the Introduction of a Trust-Type Stock Compensation Plan.”
25
Apr
Eisai Co.,Ltd. JP3160400002
2026-04-24 Eisai Co.,Ltd. “A new TV commercial campaign aimed at raising awareness of MCI (Mild Cognitive Impairment) has begun airing nationwide—"Don't Miss It, MCI ~I Was Able to Notice It Early~"—.”
25
Apr
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-04-24 DAIICHI SANKYO COMPANY,LIMITED “Notice Regarding Change in Schedule for Announcement of Financial Results for the Fiscal Year Ending March 2026 (158.1KB) (PDF file will open in a new window.)”
25
Apr
Astellas Pharma Inc. JP3942400007
2026-04-24 Astellas Pharma Inc. “Revisions past settlements and licensing agreements between MSN and Myrbetriq®.”
25
Apr
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-04-24 CHUGAI PHARMACEUTICAL CO.,LTD. “Organizational changes and personnel announcements.”
25
Apr
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-04-24 CHUGAI PHARMACEUTICAL CO.,LTD. “Consolidated financial results for the first quarter of the fiscal year ending December 2026.”
25
Apr
Kyowa Kirin Co.,Ltd. JP3256000005
2026-04-24 Kyowa Kirin Co.,Ltd. “Announcement of the commencement of a domestic Phase 2 clinical trial that forms the basis for the application for approval of ziftomenib in patients with relapsed or refractory acute myeloid leukemia who have NPM1 mutations (650KB).”
24
Apr
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-04-23 CHUGAI PHARMACEUTICAL CO.,LTD. “F. Hoffmann-La Roche's sales performance for the first quarter of 2026.”
24
Apr
Otsuka Holdings Co.,Ltd. JP3188220002
2026-04-23 Otsuka Holdings Co.,Ltd. “Paradise Ultrasound Renal Denervation System receives TAG Award in the Cardiovascular Therapy Innovation category (link to Recor English page).”
24
Apr
Kyowa Kirin Co.,Ltd. JP3256000005
2026-04-23 Kyowa Kirin Co.,Ltd. “Notice of approval for partial changes to the domestic approval of rituximab BS (4MB).”
22
Apr
Otsuka Holdings Co.,Ltd. JP3188220002
2026-04-21 Otsuka Holdings Co.,Ltd. “Regarding the Phase III STAR-121 trial of the combination of the anti-TIGIT antibody domvanalimab and the anti-PD-1 antibody zimberelimab for non-small cell lung cancer.”
22
Apr
Otsuka Holdings Co.,Ltd. JP3188220002
2026-04-21 Otsuka Holdings Co.,Ltd. “Joint research with Tokyo University of Science confirms the effectiveness of lactic acid bacteria ONRICb0240 against gingivitis, raising new expectations for oral care.”
22
Apr
Astellas Pharma Inc. JP3942400007
2026-04-21 Astellas Pharma Inc. “The FDA has accepted an application for approval of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab, regardless of whether cisplatin is indicated, as a neoadjuvant therapy for muscle-invasive bladder cancer, and has granted it priority review.”
22
Apr
Eisai Co.,Ltd. JP3160400002
2026-04-21 Eisai Co.,Ltd. “An update on the Phase III clinical trial "LITESPARK-012," which evaluates combination therapy as a first-line treatment for patients with advanced renal cell carcinoma (RCC).”
21
Apr
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-04-20 Sumitomo Pharma Co.,Ltd. “Notice regarding the determination of the issue price and selling price, etc.”